A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1608-1613

  Jacobsen, E D ^a   Kim, H T ^b   Ho, V T ^a   Cutler, C S ^a   Koreth, J ^a   Fisher, D C ^a   Armand, P ^a   Alyea, E P ^a   Freedman, A S ^a   Soiffer, R J ^a   Antin, J H ^a  

^a Department of Medical Oncology ^*

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

allogeneic transplant; CTCL; GVHD; mycosis fungoides; NK lymphoma; T cell lymphoma

Indexed keywords

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PERIPHERAL T CELL LYMPHOMA; SEZARY SYNDROME; SKIN TUMOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054101005     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq698     Document Type: Article

References (14)

1. Rüdiger, T., Weisenburger, D.D., Anderson, J.R., et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13 (2002), 140–149.
2. Schmitz, N., Ziepert, M., Nickelsen, M., et al. T-cell lymphomas in studies of the German High-grade NHL study group (DSHNHL) [abstract]. Ann Oncol, 9(Suppl 4), 2008, 94a.
3. Armitage, J., Vose, J., Weisenburger, D., International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26 (2008), 4124–4130.
4. Rodríguez, J., Caballero, M.D., Gutiérrez, A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14 (2003), 1768–1775.
5. Reimer, P., Rüdiger, T., Geissinger, E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27 (2009), 106–113.
6. Kyriakou, C., Canals, C., Finke, J., et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27 (2009), 3951–3958.
7. Corradini, P., Dodero, A., Zallio, F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004), 2172–2176.
8. Przepiorka, D., Weisdorf, D., Martin, P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995), 825–828.
9. Gray, R.J., A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
10. Fine, J., Gray, R., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
11. Shustov, A.R., Gooley, T.A., Sandmaier, B.M., et al. Allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 150 (2010), 170–178.
12. Hamadani, M., Benson, D.M. Jr, Hofmeister, C.C., et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 15 (2009), 547–553.
13. Armand, P., Gannamaneni, S., Kim, H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 26 (2008), 5767–5774.
14. Vega, F., Medeiros, L.J., Leventaki, V., et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66 (2006), 6589–6597.